Brief: Unicycive Therapeutics Provides Regulatory Update On Lanthanum Dioxycarbonate Program
29/06/2023 22:20
Unicycive Therapeutics Inc UNCY.O :
* UNICYCIVE THERAPEUTICS PROVIDES REGULATORY UPDATE ON
LANTHANUM
DIOXYCARBONATE PROGRAM
* UNICYCIVE THERAPEUTICS: FDA ASKED CO TO PROVIDE MORE
INFORMATION
TO EVALUATE TOLERABILITY OF LDC IN PATIENTS WITH CHRONIC KIDNEY
DISEASE ON DIALYSIS
* UNICYCIVE THERAPEUTICS INC - COMPANY REQUESTED A FOLLOW-UP
MEETING WITH FDA TO DISCUSS ITS ADDITIONAL REQUESTS
Source text for Eikon: ID:nGNX3GTHPp
Further company coverage: UNCY.O
Recent news on Unicycive Therapeutics
See all newsBrief: Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors
Brief: Unicycive Therapeutics Announces Resubmission Of New Drug Application For Oxylanthanum Carbonate
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
Unicycive rises on narrower quarterly loss